Investigation of different types of nano drug delivery systems of atorvastatin for the treatment of hyperlipidemia

References

• Mathur M, Kusum Devi V. Potential of novel drug delivery strategies for the treatment of hyperlipidemia. J Drug Target. 2016;24:916–926.
   PubMed Web of Science ®Google Scholar
• McFarland AJ, Dukie SA, Arora DS, et al. Molecular mechnisms underlying the effects of statins in the central nervous system. Int J Mol Cell Med. 2014;15:20606–20637.
   Google Scholar
• Carbonell T, Freire E. Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry. 2005;44:11741–11748.
   PubMed Web of Science ®Google Scholar
• Last AR, Ference JD, Menzel ER. Hyperlipidemia: drugs for cardiovascular risk reduction in adults. Am Fam Physician. 2017;95:78–87.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Roy T. Nanoparticulate drug-delivery systems: lymphatic uptake and its gastrointestinal applications. J Appl Pharm Sci. 2014;4:123–130.
   Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.
   PubMed Web of Science ®Google Scholar
• Muller RH, Junghanns JAH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanotechnol Nanomed. 2008;3:295–309.
   Web of Science ®Google Scholar
• Loftsson T, Jarho P, Masson M, et al. Cyclodextrins in drug delivery. Expert Opin Drug Deliv. 2005;2:335–317.
   PubMed Web of Science ®Google Scholar
• Sharma M, Shah V, Pandya R, et al. Solid lipid nanospheres for atrovastatin calcium: formulation design, optimization and drug release dynamics. Pnt. 2015;3:188–204.
   Google Scholar
• Kurakula M, A. Ahmed T. Co-delivery of atorvastatin nanocrystals in PLGA based in-situ gel for anti-hyperlipidemic efficacy. Cdd. 2016;13:211–220.
   PubMed Web of Science ®Google Scholar
• Mohamed FZ, Hany MI, Mohsen IA, et al. In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. Drug Development and Industrial Pharmacy; 2018;44(8): 1243–1253. doi: 10.1080/03639045.2018.1442844.
   Google Scholar
• Bhattacharyya SP, Ghoshal I, Bhattacharyya I, et al. Flurbiprofen loaded solid lipid nanoparticles, formulation and optimization by using response surface methodology. Int J Biol Pharm Allied Sci. 2017;12:378–108.
   Google Scholar
• Shinde G, Patel M, Mehta M, et al. Formulation, optimization, and characterization of repaglinide loaded nanocrystal for diabetes therapy. Adv Pharm. 2015;2015:1.
   Google Scholar
• Ansari KA, Vavia PR, Trotta F, et al. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS Pharm Sci Tech. 2011;12:279.
   PubMed Web of Science ®Google Scholar
• Sharma D, Maheshwari D, Philip G, et al. Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using box-behnken design: in vitro and in vivo evaluation. Biomed Res Int. 2014;2014:1–14.
   Google Scholar
• Bohrey S, Chourasiya V, Pandey A. Polymeric nanoparticles containing diazepam: preparation, optimization, characterization, in-vitro drug release and release kinetic study. Nanoconvergence 2016;3. doi:10.1186/s40580-016-0061-2.
   Google Scholar
• Huseynov E, Garibov A, Mehdiyeva R. TEM and SEM study of nano SiO2 particles exposed to influence neutron flux. J. Mater. Res. Technol. 2016;5:213–218.
   Google Scholar
• Khan KA. A preclinical antihyperlipidemic evaluation of Artemisia Vulgaris root in diet induced hyperlipidemic animal model. Int J Pharmtech Res. 2015;5:510.7439/ijpr
   Google Scholar
• Mathur M, Kusumdevi V. Design of experiment utilization to develop and validate high performance liquid chromatography technique for estimation of pure drug and marketed formulations of atorvastatin in spike rat plasma samples. IJPSR. 2017;8:1708–1716.
   Google Scholar
• Avwioro G, Iyiola S, Aghoghovwia B. Histological and biochemical markers of the liver of Wistar rats on subchronic oral administration of green tea. NAJMS. 2010;2:376–380.
   PubMedGoogle Scholar
• International Council for Harmonisation (ICH). Stability testing of new drug substances and products. http://www.ich.org/fileadmin/PublicWebSite/ICHProducts/Guidelines/Quality/Q1AR2/Step4/Q1AR2Guideline.pdf (accessed 5 February 2015).
   Google Scholar
• Elmowafy M, Ibrahim HM, Ahmed MA, et al. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug Delivery. 2017;24:932–941.
   PubMed Web of Science ®Google Scholar
• Hematoxylin and eosin staining: principle, procedure and interpretation. Histopathology. 2015; Available from: www.LaboratoryInfo.com.
   Google Scholar
• Xia F, Fan W, Jiang S, et al. Size-dependent translocation of nanoemulsions via oral delivery. ACS Appl Mater Interfaces. 2017;9:21660–21672.
   PubMed Web of Science ®Google Scholar
• Bhalekar M, Upadhaya P, Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug Darunavir. Appl Nanosci. 2017;7:47–57.
   Web of Science ®Google Scholar
• Moin A, Deb TK, Osmani R, et al. Fabrication, characterization, and evaluation of microsponge delivery system for facilitated fungal therapy. J Basic Clin Pharm. 2016;7:39–48.
   PubMedGoogle Scholar
• Peltonen L, Strachan C. Understanding critical quality attributes for nanocrystals from preparation to delivery. Molecules. 2015;20:22286–22300.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Toy T. Nanoparticulate drug-delivery systems: lymphatic uptake and its gastrointestinal applications. Int. J. Appl. Pharm. 2014;4:123–130.
   Google Scholar
• Fang J, Lin Z, Chen C, et al. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal. 2017;25:219–234.
   PubMed Web of Science ®Google Scholar
• Khadka P, Ro J, Kim H, et al. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci. 2014;9:304–316.
   Google Scholar
• Kondapi AK, Golla K, Bhaskar C, et al. Improved safety, bioavailability and pharmacokinetics of zidovudine through lactoferrin nanoparticles during oral administration in rats. PLoS One. 2015;10:e0140399.
   PubMed Web of Science ®Google Scholar
• Shah NV, Seth AK, Balaraman R, et al. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J Adv Res. 2016;7:423–434.
   PubMed Web of Science ®Google Scholar
• Torne SJ, Ansari KA, Vavia PR, et al. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv. 2010;17:419–425.
   PubMed Web of Science ®Google Scholar
• Cerqueira NMFSA, Oliveira EF, Gesto DS, et al. Cholesterol biosynthesis: a mechanistic overview. Biochemistry. 2016;55:5483–5506.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lee SH, Feng SS. Folate-decorated poly(lactide-coglycolide)- vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials. 2007;28:1889–1899.
   PubMed Web of Science ®Google Scholar
• Hoshyar N, Gray S, Han H, et al. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine. 2016;11:673–692.
   PubMed Web of Science ®Google Scholar
• Kumar R, Roy I, Ohulchanskky TY, et al. In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano. 2010;4:699–708.
   PubMed Web of Science ®Google Scholar
• Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 2015;10:13–23.
   Web of Science ®Google Scholar
• Walsh KM, Albassam MA, Clarke DE. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. Toxicol Pathol. 1996;24:468–476.
   PubMed Web of Science ®Google Scholar